Learn more about Germany's leading Connected Care platform and the life-changing research that makes it possible.
Noah Labs is harnessing the power of a patient's voice to detect decompensation of heart failure early. Noah Labs is at the forefront of AI development and innovation in cardiac care and is currently conducting clinical trials worldwide.
Learn more about our path to clinical validation.
Partnerships and memberships:
Noah Labs is a member of the Innovators' Network of the American Heart Association.
We work hand in hand with leading research centres and clinics to explore innovative solutions and bring them from bench to bedside. We are currently involved in several clinical studies, being at the forefront of driving the development of precise, reliable, and user-friendly health solutions.
Noah Labs Vox uses voice samples from heart failure patients to calculate acoustic parameters that are used to assess and predict the patients' state of health. This enables changes in health status to be detected at an early stage.
We are working with leading global institutions to ensure that our AI-based Noah Labs Vox technology can predict acute decompensation in heart failure patients 14-21 days before hospitalisation by analysing changes in their voices.
Note: Noah Labs Vox is a medical device that currently undergoes clinical trials.
The world's most renowned university hospitals, such as the Mayo Clinic and the German Heart Centre at the Charité, are evaluating the groundbreaking biomarker researched at Noah Labs.
The aim of the project is to improve medical care for patients with chronic heart failure by using an artificial intelligence (AI)-supported remote patient management system. In Germany, approximately 2.5 million patients suffer from chronic heart failure (1). Every year, 487,247 inpatients are treated (2019) (2). Heart failure (HF) is thus the most common reason for illness-related hospitalisations, with annual treatment costs of almost 5.3 billion euros (2015) (3). Approximately 85% of the costs are incurred by inpatient stays (4). It is therefore a major challenge to reduce the number of hospitalisations by improving (outpatient) heart failure care.
A new study is being conducted in a collaboration between Noah Labs, the German Heart Centre Charité and the renowned Mayo Clinic in the US that could revolutionise the possibilities of telemedical monitoring of patients with advanced heart failure.
The initial focus is on patients with advanced heart failure who are suffering from ‘hydropic decompensation’. This condition occurs when the heart is no longer able to pump enough fluid out of the tissue due to reduced pumping function, causing fluid to accumulate in the body, which can lead to life-threatening complications.
.svg)
.svg)
Noah Labs is contributing its expertise as project lead in the development of AI-supported solutions for the management of cardiovascular diseases. ‘We are thrilled to be at the forefront of this groundbreaking research,’ says Dr Leonhard Riehle, Chief Medical Officer and Co-Founder of Noah Labs. ’By working with renowned medical institutions such as Maastricht UMC+ and Clinic Barcelona, we are confident that this project will bring us closer to our shared mission: helping people with chronic conditions live longer, healthier lives.’
The aim of the study is to evaluate the effectiveness of language analysis in detecting early warning signs and predicting ADHF exacerbations. This breakthrough approach has the potential to revolutionise the treatment of ADHF by providing a non-invasive and cost-effective means of early detection, leading to better treatment outcomes and fewer hospitalisations.
Noah Labs combines groundbreaking technology and life-changing research to create a future of unparalleled well-being and joy. Here's how this future could look in numbers:
.png)
